PATENT CLAIM ANALYSIS

Application Number: 16105203
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["435", "194000"]

Abstract:
The present invention relates to the construction of a new class of Targeted Secretion Inhibitors (TSIs), which comprise a non-cytotoxic protease, translocation peptide and a targeting moiety peptide, wherein the targeting moiety peptide has a free N-terminal domain and a free C-terminal domain; to a single-chain fusion protein precursor thereof, and to a method of activating said single-chain fusion protein precursor.

Claim (Index 6):
The nucleic acid of  claim 1 , wherein a short polypeptide that provides a secondary polypeptide structure is located between the translocation domain of the fusion protein of the fusion protein and the targeting moiety and the secondary polypeptide structure acts to bring part of the targeting moiety into close proximity to the translocation domain, thereby making formation of the covalent linkage energetically more favorable.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 96.0
- Lexical Diversity: 1.60465
- Patent Class: 435.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14117286', '13774587', '12862948', '13738235', '13239573']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6539738831156593
- 35 USC 102 Novelty (BERT): 0.581367930280651
- Combined Prediction Score: 0.6467132878321584
- Mean Citation Score: 420.549464
- Max Citation Score: 466.78696
- Similarity Product: 443.7434448955346

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test